Fresenius Medical Care Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Fresenius Medical Care wird ein jährliches Gewinn- und Umsatzwachstum von 22.2% bzw. 3.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.8% betragen.
Wichtige Informationen
21.9%
Wachstumsrate der Gewinne
21.3%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 20.6% |
| Wachstumsrate der Einnahmen | 3.6% |
| Zukünftige Eigenkapitalrendite | 7.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 24 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We Think Fresenius Medical Care (ETR:FME) Is Taking Some Risk With Its Debt
Sep 26
These Return Metrics Don't Make Fresenius Medical Care (ETR:FME) Look Too Strong
Sep 08At €34.34, Is Fresenius Medical Care AG (ETR:FME) Worth Looking At Closely?
Aug 20Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 02These 4 Measures Indicate That Fresenius Medical Care (ETR:FME) Is Using Debt Extensively
Jun 17What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
May 30Some Shareholders May Object To A Pay Rise For Fresenius Medical Care AG's (ETR:FME) CEO This Year
May 10Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19
Apr 26Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 29Fresenius Medical Care (ETR:FME) Has Announced That It Will Be Increasing Its Dividend To €1.19
Mar 14Fresenius Medical Care's (ETR:FME) Dividend Will Be Increased To €1.19
Feb 23When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Feb 22Market Participants Recognise Fresenius Medical Care AG's (ETR:FME) Earnings
Feb 03Fresenius Medical Care (ETR:FME) Could Be Struggling To Allocate Capital
Jan 16Is Fresenius Medical Care (ETR:FME) Using Too Much Debt?
Dec 29Is There Now An Opportunity In Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Nov 21Capital Allocation Trends At Fresenius Medical Care KGaA (ETR:FME) Aren't Ideal
Oct 16Is Fresenius Medical Care KGaA (ETR:FME) A Risky Investment?
Sep 28Is Now The Time To Look At Buying Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Aug 21An Intrinsic Calculation For Fresenius Medical Care AG & Co. KGaA (ETR:FME) Suggests It's 34% Undervalued
Jul 23Returns On Capital At Fresenius Medical Care KGaA (ETR:FME) Paint A Concerning Picture
Jul 09These 4 Measures Indicate That Fresenius Medical Care KGaA (ETR:FME) Is Using Debt Extensively
Jun 25What Does Fresenius Medical Care AG & Co. KGaA's (ETR:FME) Share Price Indicate?
May 07Is There An Opportunity With Fresenius Medical Care AG & Co. KGaA's (ETR:FME) 49% Undervaluation?
Apr 23We Think Fresenius Medical Care KGaA (ETR:FME) Is Taking Some Risk With Its Debt
Mar 24Should You Think About Buying Fresenius Medical Care AG & Co. KGaA (ETR:FME) Now?
Feb 03Are Investors Undervaluing Fresenius Medical Care AG & Co. KGaA (ETR:FME) By 45%?
Jan 19Fresenius Medical Care KGaA (ETR:FME) Might Be Having Difficulty Using Its Capital Effectively
Jan 04Fresenius Medical Care KGaA (ETR:FME) Takes On Some Risk With Its Use Of Debt
Dec 17Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 20,772 | 1,098 | 1,890 | 2,729 | 15 |
| 12/31/2025 | 19,999 | 923 | 1,957 | 2,567 | 18 |
| 12/31/2024 | 19,376 | 652 | 1,990 | 2,383 | 18 |
| 6/30/2024 | 19,415 | 530 | 1,342 | 2,049 | N/A |
| 3/31/2024 | 19,474 | 484 | 1,911 | 2,613 | N/A |
| 12/31/2023 | 19,454 | 499 | 1,918 | 2,629 | N/A |
| 9/30/2023 | 19,463 | 450 | 1,799 | 2,509 | N/A |
| 6/30/2023 | 19,622 | 596 | 1,674 | 2,407 | N/A |
| 3/31/2023 | 19,554 | 602 | 1,401 | 2,152 | N/A |
| 12/31/2022 | 19,398 | 673 | 1,397 | 2,167 | N/A |
| 9/30/2022 | 19,048 | 763 | 1,444 | 2,237 | N/A |
| 6/30/2022 | 18,393 | 806 | 1,444 | 2,271 | N/A |
| 3/31/2022 | 17,957 | 878 | 1,576 | 2,441 | N/A |
| 12/31/2021 | 17,619 | 969 | 1,603 | 2,489 | N/A |
| 9/30/2021 | 17,372 | 918 | 1,477 | 2,405 | N/A |
| 6/30/2021 | 17,344 | 998 | 1,480 | 2,459 | N/A |
| 3/31/2021 | 17,581 | 1,131 | 2,869 | 3,857 | N/A |
| 12/31/2020 | 17,859 | 1,164 | 3,148 | 4,233 | N/A |
| 9/30/2020 | 18,039 | 1,330 | 3,299 | 4,420 | N/A |
| 6/30/2020 | 18,044 | 1,309 | 3,377 | 4,542 | N/A |
| 3/31/2020 | 17,832 | 1,212 | 1,832 | 3,075 | N/A |
| 12/31/2019 | 17,477 | 1,200 | 1,404 | 2,567 | N/A |
| 9/30/2019 | 17,196 | 1,282 | 1,367 | 2,494 | N/A |
| 6/30/2019 | 16,835 | 1,234 | 1,246 | 2,379 | N/A |
| 3/31/2019 | 16,704 | 1,974 | 1,065 | 2,182 | N/A |
| 12/31/2018 | 16,547 | 1,982 | 920 | 2,062 | N/A |
| 9/30/2018 | 16,676 | 1,951 | 766 | 1,892 | N/A |
| 6/30/2018 | 16,954 | 1,975 | 684 | 1,750 | N/A |
| 3/31/2018 | 17,211 | 1,250 | N/A | 1,977 | N/A |
| 12/31/2017 | 17,784 | 1,280 | N/A | 2,192 | N/A |
| 9/30/2017 | 17,771 | 1,249 | N/A | 2,436 | N/A |
| 6/30/2017 | 17,647 | 1,244 | N/A | 2,217 | N/A |
| 3/31/2017 | 17,201 | 1,239 | N/A | 1,938 | N/A |
| 12/31/2016 | 16,570 | 1,144 | N/A | 1,932 | N/A |
| 9/30/2016 | 16,101 | 1,063 | N/A | 1,648 | N/A |
| 6/30/2016 | 15,841 | 998 | N/A | 1,782 | N/A |
| 3/31/2016 | 15,402 | 933 | N/A | 1,491 | N/A |
| 12/31/2015 | 15,455 | 955 | N/A | 1,767 | N/A |
| 9/30/2015 | 15,345 | 939 | N/A | 1,791 | N/A |
| 6/30/2015 | 15,246 | 948 | N/A | 1,914 | N/A |
| 3/31/2015 | 15,428 | 977 | N/A | 2,044 | N/A |
| 12/31/2014 | 13,329 | 864 | N/A | 1,538 | N/A |
| 9/30/2014 | 12,413 | 839 | N/A | 1,476 | N/A |
| 6/30/2014 | 11,112 | 775 | N/A | 1,283 | N/A |
| 3/31/2014 | 10,882 | 791 | N/A | 1,329 | N/A |
| 12/31/2013 | 10,816 | 806 | N/A | 1,478 | N/A |
| 9/30/2013 | 10,881 | 752 | N/A | 1,491 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: FMEDas prognostizierte Gewinnwachstum (22.2% pro Jahr) liegt über der Sparquote (0.8%).
Ertrag vs. Markt: FMEDie Erträge des Unternehmens (22.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (20% pro Jahr).
Hohe Wachstumserträge: FMEEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: FMEDie Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt German (5.3% pro Jahr).
Hohe Wachstumseinnahmen: FMEDie Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: FMEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.8%).